Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

LambdaVision Inc.

Restoring sight with light-activated proteins

This article was originally published in Start Up

Executive Summary

Artificial retinal prostheses are poised to make a dramatic impact by restoring at least partial vision to people blinded by degenerative ophthalmic diseases. A number of companies are developing complex implantable microelectronic innovations, many with external hardware components, to stimulate the retina and overcome the photoreceptor cell deterioration that is the hallmark of these diseases. LambdaVision Inc. is taking a unique approach to restoring vision by developing a flexible, protein-based retinal implant designed to provide higher resolution and to be less surgically invasive than competing technologies.

You may also be interested in...



Artificial Retinal Devices Help The Blind To See

Worldwide rates of all diseases that cause blindness are expected to double by 2020 due to the aging population, making this an area ripe for medical device innovation. A multibillion-dollar market has been built around the surgical correction of "front of the eye" age-related vision disorders such as presbyopia, but the technological evolution in ophthalmology has now reached the back of the eye. Artificial retinal prostheses are an increasingly popular area of investigation. Start-ups hoping to enter this market face daunting R&D, clinical and regulatory hurdles, and will require significant resources. We profile three such companies in this issue: 2C Tech Corp., LambdaVision and Nano Retina.

EU Joint Regulatory Assessment Project Bears Fruit In COVID-19

The European Medicines Agency has reported progress with a collaborative project that involves other regulators in its assessments of COVID-19 products, and with the EU Medicines for All initiative for evaluating products for non-EU markets.

The Case For Covaxin: Ocugen CEO Shankar Musunuri

A potential decline in mRNA vaccine protection against the Delta variant is raising questions about the need for booster shots in the US. Ocugen Inc. and partner Bharat Biotech hope the changing dynamic of COVID-19 in the US will induce the FDA to reconsider additional clinical trial requirements for Covaxin, an inactivated whole virus vaccine authorized for emergency use in 16 countries. 

Topics

Related Companies

UsernamePublicRestriction

Register

MT037755

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel